Created for
Life Sciences Founders

We help life sciences founders streamline partnering and fundraising through expert strategy, targeted outreach, and aligned support—often co-investing ourselves—all at a fraction of the cost of traditional advisors.

Who We Are

We spare life sciences founders from unruly outdated partnering spreadsheets, missed emails and lost opportunities, and the daunting maze of pharma partnering teams, all in a fraction of the cost of a full-time business development advisor or an investment bank.

As former corporate development executives and strategy operators, we validate and hone your strategy, identify blind spots, streamline the partner outreach process, and flex our connections to assure you have a fair shot at fundraising, research collaborations and outlicensing.

We are not brokers and do not take a commission on equity funding. In fact, we frequently co-invest in our clients, assuring long term alignment of interests.

Dealmaking 601: Module 2: Crafting Problem Statements

If there’s one question that holds the key to securing funding, it’s this: “Why would I buy this from you now?” Surprisingly, many founders, myself included, struggle to answer it convincingly at first. Entrepreneurship often begins with a spark—an eureka moment, promising lab results, or a convincing friend. It’s driven by passion, grit, and creativity, where feelings outweigh logic. Potential investors operate in the opposite realm. They encounter countless ideas daily and employ a structured, disciplined approach rooted in logic and process. The bridge between these worlds lies in your ability to answer that pivotal question. In this brief video, I dissect the answer into its four essential elements.

Insights from Our Collaborators

"Onne assisted the scientific founder of Abreos in closing the transaction. I would not hesitate to hire him again."




 Neil Senturia CEO, Blackbird ventures "Onne helped us bring on Eli Lilly which joined our Series A round…He was also critical in establishing a relationship with the CMTRF (Charcot Marie Tooth Research Foundation). The CMT1A asset was a key value driver from our acquisition." Arthur Suckow PhD, CEO, DTX Pharma
(sold to Novartis for $1B) "I look forward to working with Onne throughout my career."





 Prof. James Basilion Case Western Reserve University "Onne’s energy and dedication and his experience in both startup and larger corporate settings have significantly contributed to our company's growth efforts."


 Prof. Florian Solzbacher CEO, Blackbird ventures "Onne represented us thoughtfully in calls, trade shows, and virtual meetings, and I trusted him to continue driving this opportunity forward."



 Francois Michelon CEO, Endra lifesciences "Onne helped us understand the market better, faster (and cheaper,) than any other consultant I've worked with. I was also impressed by his network."



 Aditya Rajagopal co-CEO, Esperto Healthcare "Onne was very helpful in preparing us for our latest funding round."





 Michael Thornton CTO, Endra Lifesciences